📰 Hematology Development News
Page 5 - Hematology Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hematology Development. Real-time updates on events, politics, business and more.
October 28, 2021
Novartis is eyeing approval for Kymriah to treat adult patients with relapsed or refractory follicular lymphoma - News - PharmaTimes
June 11, 2021
Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-week interval In the study, 89.6% of patients treated with Reblozyl remained transfusion free vs. 67.3% of patients in the placebo arm at weeks 1-24 Results featured in Presidential Symposium of European Hematology Association’s Virtual Congress as one of top six abstracts submitted Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc....
April 23, 2021
If approved, Onureg will become the first and only once daily oral frontline maintenance therapy in Europe for patients with a broad range of acute myeloid leukemia subtypes In the pivotal QUAZAR ® AML-001 study, Onureg demonstrated significant overall survival and showed a relapse-free survival benefit in patients with AML in first remission Bristol Myers Squibb today announced the Committee for Medicinal Products … If approved, Onureg will become the first and only once daily oral frontli...